KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Current Deferred Revenue (2018 - 2025)

Adaptive Biotechnologies' Current Deferred Revenue history spans 8 years, with the latest figure at $46.2 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 17.04% to $46.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.2 million, a 17.04% decrease, with the full-year FY2025 number at $46.2 million, down 17.04% from a year prior.
  • Current Deferred Revenue hit $46.2 million in Q4 2025 for Adaptive Biotechnologies, up from $42.5 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for ADPT hit a ceiling of $114.2 million in Q1 2023 and a floor of $42.5 million in Q3 2025.
  • Historically, Current Deferred Revenue has averaged $72.3 million across 5 years, with a median of $79.0 million in 2021.
  • Biggest five-year swings in Current Deferred Revenue: soared 46.61% in 2023 and later crashed 49.73% in 2025.
  • Tracing ADPT's Current Deferred Revenue over 5 years: stood at $80.5 million in 2021, then dropped by 20.31% to $64.1 million in 2022, then dropped by 24.15% to $48.6 million in 2023, then rose by 14.52% to $55.7 million in 2024, then decreased by 17.04% to $46.2 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ADPT at $46.2 million in Q4 2025, $42.5 million in Q3 2025, and $55.3 million in Q2 2025.